Company news
Beijing Hotgen Biotech Co. Ltd. news in 2026
Beijing Hotgen Biotech Co. Ltd.'s news releases, calls and decks from 2026, newest first.
(688068)"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Progress of Sale of Repurchased Shares
November 2, 2026
(688068)"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Voluntary Disclosure of Completion of First Subject Enrollment and Dosing in the Phase II Clinical Study of the Subsidiary's SGC001 Innovative Drug for Indication of "Predicted Severe Acute Pancreatitis"
October 15, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
September 18, 2026
Announcement on Voluntary Disclosure of Completion of First Subject Enrollment and Dosing in the Phase I/IIa Clinical Trial of Subsidiary's Innovative Drug SGT003
September 14, 2026
Announcement on Change of Registered Capital, Amendment to the Articles of Association and Filing of Industrial and Commercial Registration Changes
August 26, 2026
Announcement on Implementation Results of Share Repurchase and Share Changes
August 7, 2026
Announcement on Adjustment of Core Technical Personnel
August 3, 2026
Announcement on Voluntary Disclosure of Obtaining "Drug Clinical Trial Approval" for New Indication of Subsidiary's Innovative Drug SGC001 Injection
July 31, 2026
Announcement on Abnormal Fluctuations in Stock Trading
July 2, 2026
Announcement on Progress in Repurchasing Shares
July 1, 2026
Announcement on Voluntary Disclosure of Obtaining the "Drug Clinical Trial Approval Notice" for Subsidiary’s Innovative Drug SGT003 Injection
June 17, 2026
Announcement on Progress in Repurchasing Shares
June 1, 2026
Announcement on Shareholding of Top 10 Shareholders and Top 10 Shareholders Without Sales Restrictions Concerning Share Repurchase
May 27, 2026
Announcement on Initial Share Repurchase by the Company via Call Auction
May 25, 2026
Announcement on Early Termination of the Repurchased Shares Sale Plan and the Results of the Sale of Repurchased Shares
May 21, 2026
Announcement on Serious Abnormal Fluctuations in Stock Trading
May 19, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 18, 2026
Announcement on Capital Increase of Joint Stock Company and Related Party Transactions
May 15, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
May 11, 2026
Announcement on Progress and Implementation Result of Shares Repurchase and Share Changes
May 7, 2026
Announcement on Canceling Some Restricted Stocks Granted and Not Yet Vested
April 24, 2026
Announcement on Voluntary Disclosure of Obtaining the "Acceptance Notice" for Clinical Trial Application for Subsidiary’s Innovative Drug SGT003 Injection
April 10, 2026
Announcement on Progress in Disposal of Repurchased Shares
April 2, 2026
Announcement on Initial Sale of Repurchased Shares Through Call Auction
March 31, 2026
Announcement on Voluntary Disclosure of Completion of the First Patient Enrollment and Dosing in the Phase II Clinical Trial of SGC001 Innovative Drug by a Subsidiary
March 10, 2026
Announcement on Voluntary Disclosure of the Completion of First Patient Enrollment and Dosing in the Phase Ib Clinical Trial of Innovative Drug AA001 Monoclonal Antibody for Alzheimer’s Disease by an Joint-stock Company
March 2, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 26, 2026
Earnings Preannouncement for 2025
January 16, 2026